IMCR stock icon

Immunocore
IMCR

$39
6%

Market Cap: 1.95B

 

About: Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.

Employees: 497

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 21 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

493% more call options, than puts

Call options by funds: $49.2M | Put options by funds: $8.29M

100% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 14

63% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 38

11% more funds holding

Funds holding: 131 [Q4 2023] → 145 (+14) [Q1 2024]

4.72% more ownership

Funds ownership: 77.96% [Q4 2023] → 82.68% (+4.72%) [Q1 2024]

5% more capital invested

Capital invested by funds: $2.56B [Q4 2023] → $2.68B (+$116M) [Q1 2024]

13% less funds holding in top 10

Funds holding in top 10: 8 [Q4 2023] → 7 (-1) [Q1 2024]

Research analyst outlook

21 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$63
62%
upside
Avg. target
$84
115%
upside
High target
$100
156%
upside

21 analyst ratings

19 positive
90%
neutral
10%
negative
0%
JP Morgan
Jessica Fye
69%upside
$66
Overweight
Maintained
10 Jul 2024
HC Wainwright & Co.
Patrick Trucchio
156%upside
$100
Buy
Reiterated
5 Jun 2024
Needham
Gil Blum
108%upside
$81
Buy
Reiterated
3 Jun 2024
HC Wainwright & Co.
Patrick Trucchio
156%upside
$100
Buy
Reiterated
30 May 2024
Needham
Gil Blum
108%upside
$81
Buy
Reiterated
29 May 2024

Financial journalist opinion